IgA Antibody Screening for Necrotizing Enterocolitis Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Necrotizing enterocolitis (NEC) in newborn premature infants is a severe condition with high mortality and long-term consequences, and current treatments are costly and often ineffective, with the exact protective mechanisms of breast milk against NEC not fully understood.
Innovation Solution
Development of methods to detect and administer antibodies, particularly immunoglobulin A (IgA), that bind to bacteria associated with NEC, using bacterial arrays and breast milk, to treat and prevent the disease by enhancing intestinal microbiota protection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatment methods are used for NEC, then the disease can be treated, but the treatment cost is extremely high and often ineffective
Solution Approach 1:
The patent extracts and isolates specific antibodies (particularly IgA) from breast milk that have the ability to bind to NEC-associated bacteria. By identifying and separating these protective antibodies from the complex breast milk matrix, the invention creates a targeted therapeutic agent that addresses the root cause of NEC without requiring expensive broad-spectrum treatments
Solution Approach 2:
The patent uses antibodies as intermediary molecules that mediate the protective effect between breast milk and NEC-associated bacteria. These antibodies serve as specific mediators that bind to bacterial targets, preventing bacterial adhesion and colonization in the infant intestine, thereby providing targeted protection against NEC
2Reliability
If breast milk is administered to prevent NEC, then the incidence of NEC is reduced, but the protective mechanisms are not fully understood
Solution Approach 1:
The patent replaces the complex, poorly understood mechanical system of breast milk protection with a well-defined molecular mechanism. By identifying specific antibodies and their binding interactions with NEC-associated bacteria, the invention substitutes the vague concept of 'breast milk protection' with a precise molecular mechanism involving antibody-antigen recognition and binding
Solution Approach 2:
The patent employs detection methods that provide feedback on antibody-bacteria binding interactions. By using bacterial arrays and detection systems to monitor which antibodies bind to which bacteria, the invention creates a feedback loop that reveals the specific protective mechanisms, transforming the previously unknown protection process into a measurable and understandable system
3Reliability
If multiple surgeries are performed to treat NEC, then the disease can be managed, but long-term consequences such as failure to thrive occur
Solution Approach 1:
The patent applies preliminary protective action by administering antibodies (either from breast milk or isolated therapeutically) to infants before NEC develops or in early stages. This preliminary intervention prevents bacterial colonization and intestinal damage before they occur, avoiding the need for subsequent surgeries and preventing long-term consequences like failure to thrive
Solution Approach 2:
The patent implements preliminary anti-action by using antibodies to counteract the harmful effects of NEC-associated bacteria before they can cause significant damage. The antibodies bind to bacteria in advance, preventing their adhesion and invasion of the intestinal tissue, thereby preemptively neutralizing the disease-causing mechanisms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The administration of IgA antibodies from breast milk effectively reduces the incidence and severity of NEC by binding to pathogenic bacteria, preventing intestinal damage and inflammation, as demonstrated in both human and murine models.
Implementation Method 1
administering the sample including the antibody that binds to the bacterium associated with NEC to the infant
Data Source
AI summary
Provided are antibodies that bind to bacteria associated with necrotizing enterocolitis (NEC), methods of detecting the same, and methods of using the same for treating and/or preventing NEC. The antibodies that bind to bacteria associated with NEC are detected by, e.g., detecting binding of the antibody to a bacterium in a bacterial array that includes the bacteria associated with NEC.